Cobalt ferrite nanoparticle for the elimination of CD133+CD44
Cancer stem cell (CSC)
Photodynamic therapy (PDT) and magnetic hyperthermia (MHT)
Photothermal therapy (PTT)
Superparamagnetic nanoparticle
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
03
06
2023
revised:
02
09
2023
accepted:
05
09
2023
medline:
9
10
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
epublish
Résumé
Cancer stem cells (CSCs) are the most challenging issue in cancer treatment, because of their high resistance mechanisms, that can cause tumor recurrence after common cancer treatments such as drug and radiation based therapies, and the insufficient efficiency of common treatments in CSCs removal and the recurrence of tumors after these treatments, it is essential to consider other methods, including non-ionizing treatments likes light-based treatments and magnetic hyperthermia (MHT). After synthesis, characterization and investigation, the toxicity of novel on A375 and MAD-MB-231 cell lines, magnetic hyperthermia and light-based treatments were applied. MTT assay and flow cytometry was employed to determine cell survival. the influence of combination therapy on CD44 + CD24 The final nanoparticle has a high efficiency in producing hydroxyl radicals and generating heat in MHT. According to CIs, we can conclude that combined using of light-based treatment and MHT in the presence of final synthesized nanoparticle have synergistic effect and a high ability to reduce the population of stem cells in both cell lines compared to single treatments. In this study a novel multi-functional nanoplatform acted well in dual and triple combined treatments, and showed a good performance in the eradication of CSCs, in A375 and MAD-MB-231 cell lines
Sections du résumé
Background
UNASSIGNED
Cancer stem cells (CSCs) are the most challenging issue in cancer treatment, because of their high resistance mechanisms, that can cause tumor recurrence after common cancer treatments such as drug and radiation based therapies, and the insufficient efficiency of common treatments in CSCs removal and the recurrence of tumors after these treatments, it is essential to consider other methods, including non-ionizing treatments likes light-based treatments and magnetic hyperthermia (MHT).
Method and material
UNASSIGNED
After synthesis, characterization and investigation, the toxicity of novel on A375 and MAD-MB-231 cell lines, magnetic hyperthermia and light-based treatments were applied. MTT assay and flow cytometry was employed to determine cell survival. the influence of combination therapy on CD44 + CD24
Result
UNASSIGNED
The final nanoparticle has a high efficiency in producing hydroxyl radicals and generating heat in MHT. According to CIs, we can conclude that combined using of light-based treatment and MHT in the presence of final synthesized nanoparticle have synergistic effect and a high ability to reduce the population of stem cells in both cell lines compared to single treatments.
Conclusion
UNASSIGNED
In this study a novel multi-functional nanoplatform acted well in dual and triple combined treatments, and showed a good performance in the eradication of CSCs, in A375 and MAD-MB-231 cell lines
Identifiants
pubmed: 37810832
doi: 10.1016/j.heliyon.2023.e19893
pii: S2405-8440(23)07101-3
pmc: PMC10556613
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e19893Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nat Commun. 2017 Aug 25;8(1):357
pubmed: 28842577
ACS Omega. 2020 Sep 02;5(36):23378-23384
pubmed: 32954190
Theranostics. 2016 Mar 21;6(6):762-72
pubmed: 27162548
Contrast Media Mol Imaging. 2007 Jul;2(4):199-205
pubmed: 17712863
Theranostics. 2017 Apr 10;7(6):1650-1662
pubmed: 28529642
Photodiagnosis Photodyn Ther. 2023 Sep;43:103648
pubmed: 37315828
Lancet Oncol. 2010 Jun;11(6):561-70
pubmed: 20434400
Biomaterials. 2019 Oct;219:119374
pubmed: 31369897
Nanotoxicology. 2017 Mar;11(2):278-288
pubmed: 28248593
Nano Life. 2015 Jun 19;5(2):
pubmed: 26884816
Int J Cancer. 2003 Dec 20;107(6):941-8
pubmed: 14601053
Acta Biomater. 2016 Oct 1;43:251-261
pubmed: 27422197
Front Immunol. 2020 Aug 07;11:1280
pubmed: 32849491
IET Nanobiotechnol. 2020 Jul;14(5):396-404
pubmed: 32691742
Autophagy. 2013 Sep;9(9):1292-307
pubmed: 23800749
Cell Metab. 2020 Sep 1;32(3):341-352
pubmed: 32668195
Turk J Pharm Sci. 2017 Aug;14(2):169-173
pubmed: 32454609
Chem Rev. 2014 Nov 12;114(21):10869-939
pubmed: 25260098
Int J Mol Sci. 2021 Jun 19;22(12):
pubmed: 34205414
Turk J Chem. 2020 Oct 26;44(5):1366-1375
pubmed: 33488236
J Cell Mol Med. 2009 Aug;13(8B):2236-2252
pubmed: 18681906
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188332
pubmed: 31751601
Nat Nanotechnol. 2007 Sep;2(9):577-83
pubmed: 18654371
Curr Mol Med. 2022;22(6):506-513
pubmed: 33653247
Chem Sci. 2022 May 17;13(23):6842-6851
pubmed: 35774154
Clin Dev Immunol. 2012;2012:708036
pubmed: 22693526
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):129-34
pubmed: 14688406
J Regen Med Tissue Eng. 2013 May;2:
pubmed: 24194979
J Nanobiotechnology. 2022 May 12;20(1):224
pubmed: 35549715
World J Gastroenterol. 2018 Jul 21;24(27):2921-2930
pubmed: 30038461
Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):19-29
pubmed: 19451087
Clin Cosmet Investig Dermatol. 2014 May 21;7:145-63
pubmed: 24899818
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):421-431
pubmed: 28423951
J Photochem Photobiol B. 2020 Jan;203:111737
pubmed: 31862636
J Cell Physiol. 2020 Feb;235(2):790-803
pubmed: 31286518
Phys Rev Lett. 1996 Jul 8;77(2):390-393
pubmed: 10062439
Front Pharmacol. 2018 Aug 02;9:831
pubmed: 30116191
Radiat Res. 1991 Apr;126(1):88-95
pubmed: 1799401
Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17119-24
pubmed: 20855580
Biomaterials. 2015 Aug;61:229-38
pubmed: 26005762
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Nanoscale Res Lett. 2013 Sep 08;8(1):381
pubmed: 24011350
Neurosurgery. 2005 Oct;57(4):785-96; discussion 785-96
pubmed: 16239893
Adv Drug Deliv Rev. 2011 Aug 14;63(9):789-808
pubmed: 21447363
J Colloid Interface Sci. 1998 Sep 15;205(2):470-475
pubmed: 9735211
Anticancer Agents Med Chem. 2021;21(17):2429-2442
pubmed: 33342419
Adv Sci (Weinh). 2022 Jan;9(1):e2101553
pubmed: 34747157
Nat Biotechnol. 2007 Oct;25(10):1165-70
pubmed: 17891134
Sci Rep. 2017 Jul 3;7(1):4537
pubmed: 28674429